Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects

Shaheen E Lakhan, Annette Kirchgessner, Shaheen E Lakhan, Annette Kirchgessner

Abstract

Prescription stimulants are often used to treat attention deficit hyperactivity disorder (ADHD). Drugs like methylphenidate (Ritalin, Concerta), dextroamphetamine (Dexedrine), and dextroamphetamine-amphetamine (Adderall) help people with ADHD feel more focused. However, misuse of stimulants by ADHD and nonaffected individuals has dramatically increased over recent years based on students' misconceptions or simple lack of knowledge of associated risks. In this review, we discuss recent advances in the use and increasing misuse of prescription stimulants among high school and college students and athletes. Given the widespread belief that stimulants enhance performance, there are in fact only a few studies reporting the cognitive enhancing effects of stimulants in ADHD and nonaffected individuals. Student athletes should be apprised of the very serious consequences that can emerge when stimulants are used to improve sports performance. Moreover, misuse of stimulants is associated with dangers including psychosis, myocardial infarction, cardiomyopathy, and even sudden death. As ADHD medications are prescribed for long-term treatment, there is a need for long-term safety studies and education on the health risks associated with misuse is imperative.

Keywords: Amphetamine; athletes; attention deficit hyperactivity disorder; cognition; methylphenidate; misuse; performance; students.

References

    1. Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD) Neurosci. Biobehav. Rev. 2010;34:1256–1266.
    1. Advokat CD, Guidry MS, Martino BA. Licit and illicit use of medications for attention deficit hyperactivity disorder in undergraduate college students. J. Am. Coll. Health. 2008;56:601–607.
    1. Alsidawi S, Muth J, Wilkin J. Adderall induced inverted-Takotsubo cardiomyopathy. Catheter. Cardiovasc. Interv. 2011;78:910–913.
    1. Amariles P. A comprehensive literature search: drugs as possible triggers of Takotsubo cardiomyopathy. Curr. Clin. Pharmacol. 2011;6:1–11.
    1. American Psychiatric Association. DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
    1. Associated Press. ADHD exemptions on rise in MLB. New York, NY: ESPN; 2009.
    1. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Res. 2005;77:43–58.
    1. Barkley RA, Cunningham CE. Do stimulant drugs improve the academic performance of hyperkinetic children? A review of outcome studies. Clin. Pediatr. (Phila.) 1978;17:85–92.
    1. Barrett SP, Darredeau C, Brody LK, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. Can. J. Psychiatry. 2005;50:457–461.
    1. Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Silva JM, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year prospective follow-up study. Psychol. Med. 2006;36:167–179.
    1. Biederman J, Petty CR, Fried R, Kaiser R, Dolan CR, Schoenfeld S, et al. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J. Clin. Psychiatry. 2008a;69:1217–1222.
    1. Biederman J, Seidman LJ, Petty CR, Fried R, Doyle AE, Cohen DR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention deficit/hyperactivity disorder. J. Clin. Psychiatry. 2008b;69:1150–1156.
    1. Biederman J, Fried R, Petty CR, Henin A, Wozniak J, Corkum L, et al. Examining the association between stimulant treatment and cognitive outcomes across the life cycle of adults with attention-deficit/hyperactivity disorder: a controlled cross-sectional study. J. Nerv. Ment. Dis. 2012;200:69–75.
    1. Bloom B, Cohen RA. Summary health statistics for U.S. children: National Health Interview Survey, 2006. Statistics VH. 2007;234:1–79.
    1. Bogle KE, Smith BH. Illcit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr. Drug Abuse Rev. 2009;2:157–176.
    1. Bray CL, Cahill KS, Oshier JT, Peden CS, Theriaque DW, Flotte TR, et al. Methylphenidate does not improve cognitive function in healthy sleep-deprived young adults. J. Invest. Med. 2004;52:192–201.
    1. Breitenstein C, Wailke S, Bushuven S, Kamping S, Zwitserlood P, Ringelstein EB, et al. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004;29:1704–1714.
    1. Breitenstein C, Floel A, Korsukewitz C, Waike S, Bushuven S, Knecht S. A shift paradigm: from noradrenergic to dopaminergic modulation of learning? J. Neurol. Sci. 2006;248:42–47.
    1. Brignell CM, Rosenthal J, Curran HV. Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. J. Psychopharmacol. 2007;21:673–683.
    1. Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115:e749–e757.
    1. Brumaghim JT, Klormart R. Methylphenidate's effects on paired-association learning and event-related potentials of young adults. Psychophysiology. 1998;35:73–85.
    1. Burns JT, House RF, Fensch FC, Miller JG. Effects of magnesium pemoline and dextroamphetamine on human learning. Science. 1967;155:849–851.
    1. Callaway E. Presidential address. 1982: the pharmacology of human information processing. Psychophysiology. 1983;20:359–370.
    1. Camp-Bruno JA, Herting RL. Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology. 1994;115:46–52.
    1. Center for Disease Control and Prevention. Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder – United States, 2003. MMWR Morb. Mortal. Wkly. Rep. 2005a;54:842–847.
    1. Center for Disease Control and Prevention. Prevalence of diagnosis and medication treatment for attention deficit/hyperactivity disorder – United States, 2003. MMWR Morbid. Mortal. Wkly. Rep. 2005b;54:842–847.
    1. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMWR Morb. Mortal. Wkly. Rep. 2010;59:1439–1443.
    1. Chen JP. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J. Invasive Cardiol. 2007;19:E89–E92.
    1. Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L, et al. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J. Neurosci. 2009;29:4690–4696.
    1. Cooper NJ, Keage H, Hermens D, Williams LM, Debrota D, Clark CR. The dose-dependent effect of methylphenidate on performance, cognition, and psychophysiology. J. Integrative Neurosci. 2005;4:123–144.
    1. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. 2011;365:1896–1904.
    1. Department of Justice: Drug Enforcement Administration. 2008. ARCOS2-report 7, United States summary for retail drug purchases by grams weight.
    1. Dodds CM, Muller U, Clark L, van Loon A, Cools R, Robbins TW. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J. Neurosci. 2008;28:5976–5982.
    1. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29:656–679.
    1. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N. Engl. J. Med. 1999;340:780–788.
    1. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology. 1997;131:196–206.
    1. European Medicines Agency. Meeting highlights from the committee for medicinal products for human use, 16–19 July 2007. London: European Medicines Agency; 2007.
    1. Farah MJ, Halmm C, Sankoorikal G, Smith ME, Chatterjee A. When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 2009;202:541–547.
    1. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J. Clin. Psychiatry. 2010;71:754–763.
    1. Faraone SV, Biederman J, Jetton JG, Tsuang MT. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol. Med. 1997;27:291–300.
    1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2007;2:104–113.
    1. Fillmore MT, Kelly TH, Martin CA. Effects of d-amphetamine in human models of information processing and inhibitory control. Drug Alcohol Dep. 2005;77:151–159.
    1. Fitzpatrick P, Klorman R, Brumaghim JT, Keefover RW. Effects of methylphenidate on stimulus evaluation and response processes: evidence from performance and event-related potentials. Psychophysiology. 1988;25:292–304.
    1. Fleming K, Bigelow LB, Weinberger DR, Goldberg TE. Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol. Bull. 1995;31:357–362.
    1. Gandhi PJ, Ezeala GU, Luyen TT, Tu TC, Tran MT. Myocardial infarction in an adolescent taking Adderall. Am. J. Health Syst. Pharm. 2005;62:1494–1497.
    1. Greydanus DE, Strasburger VC. Adolescent medicine. Prim. Care. 2006;33:xiii–xviii.
    1. Gualtieri CT, Johnson LG. Medications do not necessarily normalize cognition in ADHD patients. J. Atten. Disord. 2008;11:459–469.
    1. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673–2683.
    1. Harris S. 2009. “I don't see it as a problem”: more medical students taking prescription stimulants, few see cause for concern.
    1. Herman L, Shtayermman O, Aksnes B, Anzalone M, Cormerals A, Liodice C. The use of prescription stimulants to enhance academic performance among college students in health care programs. J. Physician Assist. Educ. 2011;22:15–22.
    1. Hester R, Nandam LS, O'Connell RG, Wagner J, Strudwick M, Nathan PJ, et al. Neurochemical enhancement of conscious error awareness. J. Neurosci. 2012;32:2619–2627.
    1. Horrigan JP. Present and future pharacotherapeutic options for adult attention deficit/hyperactivity disorder. Exp. Opin. Psychopharmacol. 2001;2:573–586.
    1. Hurst PM, Radlow R, Chubb NC, Bagley SK. Effects of D-amphetamine on acquisition, persistence, and recall. Am. J. Psychol. 1969;82:307–319.
    1. Jacobs A. The Adderall advantage. The New York Times. 2005 Available at: .
    1. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J. Am. Acad. Child Adolesc. Psychiatry. 2007;46:989–1002.
    1. Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M. Myocardial infarction associated with Adderall XR and alcohol use in a young man. J. Am. Board Fam. Med. 2009;22:197–201.
    1. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Abuse. Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services; 2004. Monitoring the future: national survey results on drug use, 1975–2003; pp. 10–12. in NIoD, ed.
    1. Kadison R. Getting an edge – use of stimulants and antidepressants in college. N. Engl. J. Med. 2005;353:1089–1091.
    1. Kennedy RS, Odenheimer RC, Baltzley DR, Dunlap WP, Wood CD. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Aviat. Space Environ. Med. 1990;61:615–621.
    1. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United Stated: results from the national comorbidity survey replication. Am. J. Psychiatry. 2006;163:716–723.
    1. Klorman R, Bauer LO, Coons HW, Lewis JL, Peloquin J, Perlmutter RA, et al. Enhancing effects of methylphenidate on normal young adults' cognitive processes. Psychopharmacol. Bull. 1984;20:3–9.
    1. Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology. 1993;111:1–16.
    1. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psychol. 2003;64:14–18.
    1. Kollins SH. ADHD, substance use disorder, and psychostimulant treatment current literature and treatment guidelines. J. Atten. Disord. 2008;12:115–125.
    1. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of children aged 9 through 16 years. J. Am. Acad. Child Adolesc. Psychiatry. 2005;62:1142–1431.
    1. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 1997;68:2032–2037.
    1. Kumari V, Corr PJ, Mulligan OF, Cotter PA, Checkley SA, Gray IA. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man: a preliminary study. Psychopharmacology. 1997;129:271–276.
    1. Kutcher JS. Treatment of attention-deficit hyperactivity disorder in athletes. Curr. Sports Med. Rep. 2011;10:32–36.
    1. Looby A, Earleywine M. Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance. Exp. Clin. Psychopharmacol. 2011;19:433–444.
    1. Lord S, Downs G, Furlaw P, Chaudhurl A, Silverstein A, Gammaitoni A, et al. Nonmedical use of prescription opiods and stimulants among student pharmacists. J. Am. Pharm. Assoc. 2003;49:519–528.
    1. Low KG, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol. Health Med. 2002;7:283–287.
    1. Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral and subjective effects of d-ampetamine and modafinil in healthy adults. Exp. Clin. Psychopharmacol. 2007;15:123–133.
    1. Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics. 1991;32:203–208.
    1. Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB. Dextroamphetamine enhances “neural network-specific” physiological signals: a positron emission tomography rCBF study. J. Neurosci. 1996;16:4816–4822.
    1. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. NeuroImage. 2000;12:268–275.
    1. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Am. Sci. USA. 2003;100:6186–6191.
    1. McCabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addict. Behav. 2005;30:1342–1350.
    1. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst. Use Misuse. 2004;39:1095–1116.
    1. McCabe SE, Knight JR, Teter CJ, Wechsler H. Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a nationwide survey. Addiction. 2005;100:96–106.
    1. McLaughlin L. Adderall: the whole story. 2011. Available at:
    1. McNiel AD, Muzzin KB, DeWald JP, McCann AL, Schneiderman ED, Scofield J, et al. The nonmedical use of prescription stimulants among dental and dental hygiene students. J. Dental Edu. 2011;75:365–376.
    1. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 2000;20:RC65.
    1. Mintzer MZ, Griffiths RR. A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal. Psychopharmacology. 2007;192:425–440.
    1. Misener VL, Luca P, Azeke O, Crosbie J, Waldman I, Tannock R, et al. Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder. Mol. Psychiatry. 2004;9:500–509.
    1. Mitchell H. Faking ADHD Gets you into Harvard. The Daily Beast. 2012 Available at: .
    1. Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined type ADHD in the multisite study. J. Am. Acad. Child Adolesc. Psychiatry. 2009;48:484–500.
    1. Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J. Psychol. 1998;132:227–237.
    1. Musser CJ, Ahmann PA, Theye FW, Mundt P, Broste SK, Mueller-Rizner N. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J. Dev. Behav. Pediatr. 1998;19:187–192.
    1. Oken BS, Kishiyama SS, Salinsky MC. Pharmacologically induced changes in arousal: effects on behavioral and electrophysiologic measures of alertness and attention. Electroenceph Clin. Neurophysiol. 1995;95:359–371.
    1. Partridge BJ, Bell SK, Lucke JC, Yeates S, Hall WD. Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS One. 2011;6:e28416.
    1. Pelham WE, Jr, McBurnett K, Harper GW, Milich R, Murphy DA, Clinton J, et al. Methylphenidate and baseball playing in ADHD children: who's on first? J. Consult. Clin. Psychol. 1990;58:130–133.
    1. Piper BJ, Fraiman JB, Meyer JS. Repeated MDMA (“Ecstasy”) exposure in adolescent male rats alters temperature regulation, spontaneous motor activity, attention, and serotonin transporter binding. Dev. Psychobiol. 2005;47:145–157.
    1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry. 2007;164:942–948.
    1. Polchert SE, Morse RM. Pemoline abuse. JAMA. 1985;254:946–947.
    1. Putukian M, Kreher JB, Coppell DB, Glazer JL, McKeag DB, White RD. Attention deficit hyperactivity disorder and the athlete: an American Medical Society for Sports Medicine position statement. Clin. J. Sport Med. 2011;21:392–401.
    1. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzweder HS. The misuse and diversion of prescribed ADHD medications by college students. J. Atten. Disord. 2009;13:144–153.
    1. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. Dextroamphetamine: cognitive and behavioral effects in normal and prepubertal boys. Science. 1978;199:560–563.
    1. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J. Am. Acad. Child Adolesc. Psychiatry. 2000;39:1424–1431.
    1. Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C, et al. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behavior. Psychopharmacology. 1999;146:482–491.
    1. Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity/disorder. Neuroimage. 2005;25:868–876.
    1. Rosenthal E. Not acute myocardial infarction in a teenager due to Adderall XR. Pediatr. Cardiol. 2012;33:679.
    1. Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J. Royal Soc. Med. 1992;85:399–402.
    1. Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am. J. Psychiatry. 2012;169:178–185.
    1. Schmedje JF, Oman CM, Letz R, Baker EL. Effects of scopolamine and dextroamphetamine on human performance. Aviation Space Environ. Med. 1988;59:407–410.
    1. Schroeder SR, Mann-Koepke K, Gualtieri CT, Eckerman DA, Breese GR. Methylphenidate affects strategic choice behavior in normal adult humans. Pharmacol. Biochem. Behav. 1987;28:213–217.
    1. Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, et al. Effect of methylphenidate on executive functioning in adults with attention deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol. Psychiatry. 2004;56:597–606.
    1. Sciutto MJ, Nolfi CJ, Bluhm C. Effects of child gender and symptom type on referrals for ADHD by elementary school teachers. J. Emotion Behav. Disord. 2004;12:247–253.
    1. Servan-Schreiber D, Carter CS, Bruno RM, Cohen JD. Dopamine and the mechanisms of cognition: Part II. D-amphetamine effects in human subjects performing a selective attention task. Biol. Psychiatry. 1998;43:723–729.
    1. Silber BY, Croft RJ, Papafotiou K, Stough C. The acute effects of d-amphetamine and methamphtetamine on attention and psychomotor performance. Psychopharmacology. 2006;187:154–169.
    1. Smith ME, Farah MJ. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull. 2011;137:717–741.
    1. Soetens E, Dhooge R, Hueting J. Amphetamine enhances human-memory consolidation. Neurosci. Lett. 1993;161:9–12.
    1. Soetens E, Casaer S, Dhooge R, Hueting J. Effect of amphetamine on long-term retention of verbal material. Psychopharmacology. 1995;119:155–162.
    1. Sroufe LA. Ritalin gone wrong. New York Times. 2012 29 January 2012.
    1. Strauss J, Lewis JL, Klorman R, Peloquin LJ, Perlmatter RA, Salzman LF. Effects of methylphenidate on young adults performance and event-related potentials in a vigilance and a paired-associates learning test. Psychophysiology. 1984;21:609–621.
    1. Surles LK, May HJ, Garry JP. Adderall-induced psychosis in an adolescent. J. Am. Board Fam. Pract. 2002;15:498–500.
    1. Sylvester AL, Agarwala B. Acute myocardial infarction in a teenager due to Adderall XR. Pediatr. Cardiol. 2012;33:155–157.
    1. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motivations for the illicit use of prescription stimulants in an undergraduate student sample. J. Am. Coll. Health. 2005;53:253–262.
    1. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry. 1999;56:1073–1086.
    1. Tuttle JP, Scheurich NE, Ranseen J. Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students. Acad. Psychiatry. 2010;34:220–223.
    1. Unrug A, Coenen A, van Luijtelaar G. Effects of the tranquilizer diazepam and the stimulant methylphenidate on alertness and memory. Neuropsychobiology. 1997;36:42–48.
    1. Upadhyaya HP, Rose K, Wang W, O'Rourke K, Sullivan B, Deas D, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J. Child Adolesc. Psychopharmacol. 2005;15:799–809.
    1. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics. 2012;119:S99–S107.
    1. Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, et al. Blood pressure and heart rate in the mulimodal treatment of attention deficit/hyperactivity disorder study over 10 years. Am. J. Psychiatry. 2011;169:167–177.
    1. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry. 1995;52:456–463.
    1. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry. 2007;64:932–940.
    1. Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J. Neurosci. 2012;32:841–849.
    1. Ward AS, Kelly TH, Foltin RW, Fischman MW. Effects of d-amphetamine on task performance and social behavior of humans in a residential laboratory. Exp. Clin. Psychopharmacol. 1997;5:130–136.
    1. Weitzner M. Manifest anxiety, amphetamine and performance. J. Psychol. 1965;60:71–79.
    1. Weyandt LL, DuPaul G. ADHD in college students. J. Atten. Disord. 2006;10:9–19.
    1. Wilens TE. Does the medicating ADHD increase or decrease the risk for later substance abuse? Rev. Bras. Psiquiatr. 2003;25:127–128.
    1. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu. Rev. Med. 2002;53:113–131.
    1. Wilens TE, Faraone S, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004;292:619–623.
    1. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry. 2008;47:21–31.
    1. Willett RA. The effect of a stimulant and a depressant drug on the serial rote learning of nonsense syllables. Psychopharmacologia. 1962;3:23–34.
    1. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron. 2002;36:229–240.
    1. de Wit H, Crean J, Richards JB. Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans. Behav. Neurosci. 2000;114:830–837.
    1. de Wit H, Enggasser JL, Richards JB. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology. 2002;27:813–825.
    1. Zeeuws I, Soetens E. Verbal memory performance improved via an acute administration of D-amphetamine. Hum. Psychopharmacol. Clin. Exp. 2007;22:279–287.
    1. Zuvekas S, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am. J. Psychiatry. 2011;169:160–166.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe